Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients.
Serum concentrations of prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostatic specific antigen (PSA) were measured in 31 hemodialysis patients without clinical signs of malignant disease. PAP, gamma-Sm and PSA levels in serum were not significantly different between control and hemodialysis groups. A significant reduction in these tumor markers was not found after dialysis treatment. This indicates that the measurement of PAP, gamma-Sm and PSA in serum is useful for the detection of prostatic cancer in patients undergoing hemodialysis.
Sasagawa
I
I
Department of Urology, Yamagata University, School of Medicine, Japan.
Nakada
T
T
Hashimoto
T
T
Ishigooka
M
M
Kubota
Y
Y
Hirano
K
K
Hirano
J
J
Suzuki
Y
Y
D000135:Acid Phosphatase / Q000097:blood*; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D007124:Immunoenzyme Techniques; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D029584:Prostatic Secretory Proteins; D011506:Proteins / Q000032:analysis*; D011863:Radioimmunoassay; D006435:Renal Dialysis; D029589:Seminal Plasma Proteins
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D029584:Prostatic Secretory Proteins; D011506:Proteins; D029589:Seminal Plasma Proteins; C043076:beta-microseminoprotein; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen